71 related articles for article (PubMed ID: 32847369)
1. Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling.
Masand VH; Rastija V; Patil MK; Gandhi A; Chapolikar A
SAR QSAR Environ Res; 2020 Sep; 31(9):643-654. PubMed ID: 32847369
[TBL] [Abstract][Full Text] [Related]
2. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
Kumar V; Roy K
SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
[TBL] [Abstract][Full Text] [Related]
3. Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.
Masand VH; Akasapu S; Gandhi A; Rastija V; Patil MK
Chemometr Intell Lab Syst; 2020 Nov; 206():104172. PubMed ID: 33518858
[TBL] [Abstract][Full Text] [Related]
4. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
5. Biochemical screening for SARS-CoV-2 main protease inhibitors.
Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M
Law WY; Asaruddin MR; Bhawani SA; Mohamad S
BMC Res Notes; 2020 Nov; 13(1):527. PubMed ID: 33176880
[TBL] [Abstract][Full Text] [Related]
7. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
8. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
9. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM
Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293
[TBL] [Abstract][Full Text] [Related]
10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Structure-Activity Relationship Evaluation of MDA-MB-231 Cell Anti-Proliferative Leads.
Gandhi A; Masand V; Zaki MEA; Al-Hussain SA; Ghorbal AB; Chapolikar A
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443383
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
13. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
14. Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Gutierrez-Villagomez JM; Campos-García T; Molina-Torres J; López MG; Vázquez-Martínez J
J Phys Chem Lett; 2020 Oct; 11(19):8008-8016. PubMed ID: 32840378
[TBL] [Abstract][Full Text] [Related]
15. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.
Brown AS; Ackerley DF; Calcott MJ
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066278
[TBL] [Abstract][Full Text] [Related]
16. Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.
Płonka W; Paneth A; Paneth P
Molecules; 2020 Oct; 25(20):. PubMed ID: 33053830
[TBL] [Abstract][Full Text] [Related]
17. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
Huynh T; Wang H; Luan B
Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
[TBL] [Abstract][Full Text] [Related]
18. 3CL
Sisay M
Pharmacol Res; 2020 Jun; 156():104779. PubMed ID: 32247821
[No Abstract] [Full Text] [Related]
19. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
[TBL] [Abstract][Full Text] [Related]
20. Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight.
Khan MI; Khan ZA; Baig MH; Ahmad I; Farouk AE; Song YG; Dong JJ
PLoS One; 2020; 15(9):e0238344. PubMed ID: 32881907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]